Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors

Immunotherapy for metastasized non‐small‐cell lung cancer (NSCLC) can show long‐lasting clinical responses. Selection of patients based on programmed death‐ligand 1 (PD‐L1) expression shows limited predictive value for durable clinical benefit (DCB). We investigated whether early treatment effects a...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Paul van derLeest, Birgitta Hiddinga, Anneke Miedema, Maria L. Aguirre Azpurua, Naomi Rifaela, Arja terElst, Wim Timens, Harry J. M. Groen, Léon C. vanKempen, T. Jeroen N. Hiltermann, Ed Schuuring
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2021-11-01
coleção:	Molecular Oncology
Assuntos:	ctDNA droplet digital PCR ICI treatment response monitoring NSCLC PD‐L1
Acesso em linha:	https://doi.org/10.1002/1878-0261.13090
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!